Home » Education hub » World Orphan Drug Congress Europe 2025
We are thrilled to announce that we will once again sponsor and speak at World Orphan Drug Congress Europe, the largest and most established orphan drug and rare disease meeting.
Join Giulia Pierini, Partner, Strategic Patient Engagement and Advocacy, as she leads a dynamic discussion alongside key industry leaders in our working group “From Insight to Action: Leveraging Patient Experience Data Across the Rare Disease Product Lifecycle.” Don’t miss it!
Please take the opportunity to meet us at our booth to discover how we can help you navigate the complexities of rare disease product development through our continuum of patient-centric solutions. With an intense focus on the unique needs of rare disease patients, we work with you to successfully deliver life-changing treatments to patients. Visit us at booth #10.309!
October 28 | 11:30
Understanding patient experiences, preferences, and behaviors is critical to developing treatments that truly meet patient needs. Yet in rare diseases, capturing and applying these insights remains difficult due to small, diverse populations, delayed diagnoses, a lack of standardized methods, and limited regulatory guidance.
This panel will explore how both qualitative and semi-quantitative patient data can inform more effective, patient-centered decisions across the product lifecycle in the rare disease space. Experts will address key barriers, such as data integration, resource constraints, and methodological gaps, and share practical strategies and real-world examples to overcome them.
Join the panel and gain a clear view of meaningful patient experience data look like and how they can drive not only clinical development strategies but also pre-launch and market success.
Speakers:
Giulia Pierini
Partner, Strategic Patient Engagement and Advocacy
Giulia Pierini is a rare disease specialist with deep expertise in patient engagement and advocacy. With over five years dedicated to the rare disease field and more than 50 successful patient-focused projects across multiple rare and complex conditions, she has collaborated with global pharmaceutical and biotech companies to integrate patient insights into every stage of the product lifecycle. Her work has directly influenced clinical trial design, recruitment and retention strategies, long-term adherence, access, and post-launch planning – all critical to improving outcomes and ensuring patients receive timely access to life-altering therapies.
Giulia’s commitment to rare diseases is built on a unique combination of scientific, clinical, and strategic experience. She began her career as a researcher in cellular biotechnology and hematology at the University of Rome “La Sapienza,” then moved into marketing and sales roles at Johnson & Johnson and Bristol Myers Squibb, where she worked in neurosurgery, directly supporting patients and surgeons in the operating room.
Giulia is a frequent speaker at numerous conferences, webinars, and forums, where she shares real-world examples of successful patient involvement throughout the treatment lifecycle in rare disease. Her mission is to ensure that the voices of patients and caregivers, especially in the often-overlooked rare disease community, are meaningfully embedded into decisions that shape research, development, and access.
Eduardo Pérez
Engagement Manager, Patient Access and Evidence
Luca Trentin
Engagement Manager, Patient Access and Evidence
Isabel De La Paz
Engagement Manager, Patient Access and Evidence
Mireia Cortina
Principal, Patient Access and Evidence
Article
In this interview, Luca Trentin discusses the challenges faced by people with rare diseases and the steps pharma companies can take to understand and address their needs.
Article
This article explores how leveraging patient insights can help companies overcome market access barriers and improve their chances of success.
Article
Explore innovative ways to gather patient insights for your product development beyond traditional advisory boards.
Article
Explore how biotech companies can succeed in rare disease by integrating development, commercialization, and patient access.
Case Study
A global pharmaceutical company specializing in respiratory, neonatology, rare diseases, and specialty care lacked a systematic approach to enhance the recruitment and retention of diverse patient populations.
Case Study
A global pharmaceutical company specializing in rare diseases, oncology, and neurosciences sought to analyse the patient journey for progressive familial intrahepatic cholestasis.
Subscribe to our newsletter for the latest news, events, and thought leadership